Research-Only Notice & Compliance Boundary

This document is compiled strictly for educational and analytical reference purposes within laboratory, academic, and clinical research settings. The compounds discussed herein are supplied strictly as Research Use Only (RUO) chemicals and are not intended for human or veterinary consumption, diagnostic use, or therapeutic administration. AbsoluteBioLab does not provide dosing, reconstitution, or clinical administration guidelines.

SS-31 is a mitochondria-targeting research peptide that has emerged as one of the most rigorously studied small tetrapeptides in the field of bioenergetics and oxidative stress biology. Also known by its investigational drug designation Elamipretide, and catalogued under the systematic name D-Arg-2′6′-Dmt-Lys-Phe-NH₂, SS-31 occupies a uniquely compelling position in contemporary pre-clinical research owing to its capacity to selectively concentrate within the inner mitochondrial membrane.

For researchers working at the intersection of cellular energetics, ageing biology, and metabolic dysfunction, the arrival of SS-31 as a well-characterised laboratory tool represented a meaningful inflection point. Unlike earlier mitochondria-targeted antioxidants that relied on lipophilic cations and membrane potential gradients for their subcellular localisation, SS-31 achieves its inner mitochondrial membrane accumulation through a fundamentally different mechanism — one rooted in its direct, high-affinity interaction with cardiolipin, the signature phospholipid of the inner mitochondrial membrane. This distinction is not merely academic; it has profound implications for how researchers design experimental paradigms, interpret data, and contextualise findings within the broader landscape of mitochondrial pharmacology.

The compound was first described by Hazel Szeto and Peter Schiller, whose pioneering work on cell-permeable peptides gave rise to the broader Szeto-Schiller (SS) peptide family — a nomenclature that directly informs the compound’s common identifier. Within this family, SS-31 has attracted the greatest volume of published pre-clinical investigation, spanning cardiac ischaemia-reperfusion models, neurodegenerative disease paradigms, renal injury studies, and skeletal muscle bioenergetics research. Its research trajectory is notable not only for its breadth but for the mechanistic depth with which investigators have interrogated its interactions at the molecular level.

From a laboratory supply and research infrastructure perspective, SS-31 presents a compound of considerable analytical interest. Its tetrapeptide architecture, physicochemical sensitivity, and the precision required for its handling and storage make it an instructive case study in the operational demands of working with high-value, structurally nuanced research peptides. This overview is designed to equip researchers, procurement specialists, and laboratory managers with a thorough, evidence-grounded understanding of SS-31’s identity, structural characteristics, published research landscape, and the practical considerations that govern its responsible use within a research-only context.

SS-31 is a synthetic tetrapeptide composed of four residues arranged in the sequence D-Arg-2′,6′-Dmt-Lys-Phe-NH₂, where Dmt denotes 2′,6′-dimethyltyrosine — a non-natural aromatic amino acid that confers enhanced metabolic stability and contributes critically to the compound’s antioxidant pharmacophore. The molecular formula is C₃₂H₄₉N₉O₅ with a molecular weight of approximately 639.8 Da, placing it firmly within the low-molecular-weight peptide category that facilitates membrane permeability without the requirement for active transport mechanisms. The C-terminal amidation (–NH₂) is a deliberate synthetic modification that eliminates the free carboxylate group, thereby reducing susceptibility to carboxypeptidase-mediated degradation and modulating the overall charge distribution of the molecule.

The defining structural motif of SS-31 is its alternating arrangement of basic and aromatic residues. The basic residues — D-arginine at position 1 and lysine at position 3 — confer a net positive charge of approximately +3 at physiological pH, a property that is central to both the compound’s membrane interactions and, as will be discussed in the context of laboratory handling, its propensity for electrostatic adsorption to charged surfaces. The aromatic residues — Dmt at position 2 and phenylalanine at position 4 — provide the hydrophobic and electron-donating character necessary for intercalation into the lipid bilayer and for the scavenging of reactive oxygen species. This amphipathic, charge-alternating architecture is not incidental; it is the structural basis for the compound’s selective accumulation at the inner mitochondrial membrane, where it engages with the anionic head groups of cardiolipin through electrostatic and hydrophobic interactions simultaneously.

The incorporation of D-arginine at the N-terminus is a strategically important synthetic decision. L-amino acids are substrates for a broad range of proteolytic enzymes, and the substitution of D-arginine for its L-enantiomer at this position substantially increases the compound’s resistance to aminopeptidase activity, extending its effective half-life in biological matrices — a property of considerable relevance to researchers designing time-course experiments in cell culture or ex vivo tissue preparations. The Dmt residue similarly represents a departure from canonical tyrosine; the addition of methyl groups at the 2′ and 6′ positions of the phenolic ring sterically hinders oxidative metabolism at this position while preserving and arguably enhancing the electron-donating capacity of the aromatic system.

In its lyophilised form — the standard presentation for research-grade supply — SS-31 appears as a white to off-white powder. It is freely soluble in water and in aqueous buffers across a broad pH range, with solubility exceeding 10 mg/mL in sterile water under standard laboratory conditions. The compound demonstrates good solubility in dimethyl sulphoxide (DMSO), though aqueous reconstitution is generally preferred for biological assay applications given the potential for DMSO to confound mitochondrial membrane potential measurements. The lyophilised material is hygroscopic, necessitating careful attention to moisture exclusion during storage and handling — a point that intersects directly with the vial selection and storage protocols discussed in Section 4.

From a synthesis perspective, SS-31 is produced via solid-phase peptide synthesis (SPPS) using Fmoc chemistry, with the non-natural Dmt residue requiring custom incorporation as a protected building block. The C-terminal amide is introduced through the use of Rink amide resin. Purity characterisation of research-grade material is typically performed by reverse-phase high-performance liquid chromatography (RP-HPLC), with identity confirmation by electrospray ionisation mass spectrometry (ESI-MS). For research applications, a minimum purity threshold of ≥95% by HPLC is considered standard, with premium research-grade material routinely achieving ≥98% purity. Certificate of Analysis (CoA) documentation should include HPLC chromatogram, MS spectrum, and quantitative purity assignment as a minimum analytical package.

Contextualising SS-31 within the broader landscape of mitochondria-targeted research compounds requires a structured comparison of the parameters that most directly influence experimental design, procurement decisions, and analytical validation. The table below distils four critical specification domains, each of which carries distinct implications for laboratory practice and data integrity.

Parameter	Specification / Standard	Research Relevance
Purity Grade (RP-HPLC)	≥95% standard research grade; ≥98% premium grade. Identity confirmed by ESI-MS with CoA documentation.	Sub-95% purity introduces synthetic by-products that may confound cardiolipin-binding assays and ROS scavenging measurements, producing artefactual results.
Storage Temperature & Conditions	Lyophilised: −20 °C, desiccated, inert atmosphere. Reconstituted aliquots: −80 °C, single-use. Avoid repeated freeze-thaw cycles.	Peptide bond hydrolysis and Dmt oxidation accelerate markedly above −20 °C; degraded material yields unreliable mitochondrial membrane potential data.
Molecular Weight & Charge Profile	MW ≈ 639.8 Da; net charge +3 at physiological pH. Amphipathic architecture with alternating basic/aromatic residues.	The +3 charge drives selective cardiolipin binding independent of membrane potential, distinguishing SS-31 mechanistically from TPP-conjugated antioxidants such as MitoQ.
Analytical Validation Package	Minimum: RP-HPLC chromatogram, ESI-MS spectrum, quantitative purity assignment. Recommended addition: amino acid analysis (AAA) for absolute content determination.	Accurate molar dosing in bioenergetics assays (e.g., Seahorse XF) depends on verified peptide content; UV-based quantification alone is insufficient for Dmt-containing peptides.

All specifications reflect research-grade supply standards applicable to RUO material only. Parameters are not intended to constitute clinical or pharmaceutical release criteria.

Regulatory Compliance: Institutions procuring and utilising SS-31 for research purposes are required to operate in accordance with applicable national and institutional regulatory frameworks. In the United Kingdom, this encompasses compliance with the Health and Safety at Work Act 1974, the Control of Substances Hazardous to Health (COSHH) Regulations 2002, and any applicable provisions of the Human Tissue Act 2004 where biological specimens are involved in experimental protocols. Research programmes must maintain current COSHH risk assessments specific to peptide handling, including assessment of inhalation risk from lyophilised powder during reconstitution.

Professional Standards (GMC/HCPC): Where SS-31 research is conducted within clinical academic environments involving registered healthcare professionals, the standards of the General Medical Council (GMC) and Health and Care Professions Council (HCPC) apply to the professional conduct of those individuals. Researchers holding dual roles as clinicians and investigators must maintain clear demarcation between their research activities and any clinical responsibilities, ensuring that RUO compound handling does not intersect with patient care pathways under any circumstances.

Safeguarding — Adults and Children: Research institutions must ensure that safeguarding policies for both adults at risk and children are embedded within their governance structures. Where research involves human biological samples or participant data, institutional safeguarding leads must be identified and accessible. Any research protocol involving vulnerable populations requires independent ethical review through a recognised Research Ethics Committee (REC) and must comply with the Mental Capacity Act 2005 where applicable.

Data Protection: All research data generated using SS-31 in studies involving human-derived biological material must be managed in accordance with the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. Pseudonymisation of sample identifiers, secure data storage with role-based access controls, and defined data retention schedules are minimum requirements. Researchers should consult their institutional Data Protection Officer (DPO) prior to commencing any study involving personal or sensitive personal data.

Secure Reporting and Incident Management: Institutions must maintain clear, documented pathways for reporting adverse incidents involving research chemicals, including accidental exposure, storage failures, or supply chain integrity concerns. Incident reports should be directed to the institutional Health and Safety team and, where relevant, to the MHRA Yellow Card scheme or equivalent regulatory body. AbsoluteBioLab maintains a dedicated compliance contact for supply-related queries and encourages prompt communication of any CoA discrepancies or quality concerns identified upon receipt of material.

What distinguishes SS-31 from other mitochondria-targeted antioxidants such as MitoQ?

Unlike MitoQ, which relies on membrane potential gradients via a triphenylphosphonium cation, SS-31 accumulates at the inner mitochondrial membrane through direct cardiolipin binding. This mechanism operates independently of membrane potential, making SS-31 particularly valuable in depolarised mitochondria models. Researchers consistently note this distinction when designing ischaemia-reperfusion paradigms.

What purity grade is recommended for bioenergetics assays using Seahorse XF technology?

A minimum of ≥98% purity by RP-HPLC is strongly recommended for Seahorse XF oxygen consumption rate (OCR) assays. Impurities at lower purity grades can independently alter mitochondrial respiration, confounding dose-response relationships. Experienced investigators routinely request amino acid analysis alongside standard CoA documentation for absolute content verification.

How should lyophilised SS-31 be reconstituted for cell culture experiments?

Reconstitution in sterile, nuclease-free water to a stock concentration of 1–10 mg/mL is standard practice. Aliquots should be prepared immediately, snap-frozen, and stored at −80 °C for single use. Researchers working with primary cardiomyocytes report that aqueous reconstitution avoids the mitochondrial membrane artefacts associated with DMSO vehicle controls.

Is SS-31 stable in cell culture media over extended incubation periods?

SS-31 demonstrates reasonable stability in serum-containing media over 24-hour incubation periods, attributed to its D-arginine N-terminus conferring aminopeptidase resistance. However, activity should not be assumed beyond 24 hours without stability verification. Investigators in ageing biology studies typically validate compound integrity at each experimental time point using LC-MS analysis.

What analytical documentation should accompany a research-grade SS-31 supply?

A comprehensive Certificate of Analysis (CoA) should include RP-HPLC chromatogram with quantitative purity assignment, ESI-MS spectrum confirming molecular ion, and batch-specific storage recommendations. Premium suppliers additionally provide amino acid analysis data. Procurement specialists report that incomplete CoA documentation is the most frequent cause of delayed ethical approval for research protocols.

Can SS-31 be used in ex vivo isolated mitochondria preparations?

Yes; SS-31 is well-suited to isolated mitochondria preparations, where its cardiolipin-binding mechanism can be studied in a controlled, membrane-potential-independent context. Differential centrifugation protocols yielding high-p